Discontinued — last reported Q4 '25
Eli Lilly AOCI increased by 10.2% to -$2.88B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 33.4%, from -$4.32B to -$2.88B. Over 5 years (FY 2020 to FY 2025), AOCI shows an upward trend with a -15.0% CAGR.
A negative value (loss) often reflects a strong US dollar impacting international operations or declining values in the company's investment portfolio.
Accumulated Other Comprehensive Income (Loss) includes gains and losses that are excluded from net income because they h...
Particularly relevant for multinational corporations with significant overseas revenue and large corporate investment portfolios.
aoci| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$6.29B | -$6.17B | -$4.34B | -$4.23B | -$4.29B | -$4.30B | -$3.84B | -$3.78B | -$3.79B | -$3.78B | -$4.33B | -$4.30B | -$4.38B | -$4.27B | -$4.32B | -$3.77B | -$3.72B | -$3.21B | -$2.88B |
| QoQ Change | — | +1.8% | +29.6% | +2.7% | -1.5% | -0.2% | +10.5% | +1.8% | -0.3% | +0.1% | -14.3% | +0.6% | -1.8% | +2.4% | -1.1% | +12.7% | +1.6% | +13.7% | +10.2% |
| YoY Change | — | — | — | — | +31.8% | +30.4% | +11.5% | +10.6% | +11.6% | +11.9% | -12.5% | -13.8% | -15.6% | -12.9% | +0.1% | +12.2% | +15.1% | +25.0% | +33.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.